MedTrace Logo

Study on Hypertonic Saline Nasal Spray

NCT02100605 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-02-20

No results posted yet for this study

Summary

Phytosun decongestant nasal spray is a class I medical device registered in the European Union for the treatment of nasal congestion. The spray contains hypertonic seawater and essential oils. The objective of the study is to investigate the effects of a nasal spray, registered as a medical device under the name Phytosun Decongestant in the European Union, on speed of onset of relief of nasal congestion in 50 subjects suffering from nasal congestion associated with common cold.

Conditions

  • Nasal Congestion

Interventions

DEVICE

Phytosun, decongestant, nasal spray

one time application of the nasal spray

Sponsors & Collaborators

  • Omega Pharma

    lead INDUSTRY

Principal Investigators

  • Ron Eccles, Professor · Common Cold Centre & Healthcare Clinical Trials, Cardiff school of biosciences, Cardiff University

  • Moutaz SM Jawad, MB ChB FRCP · Cardiff University, Cardiff school of biosciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02100605 on ClinicalTrials.gov